News & Updates
Filter by Specialty:
Inhaled amikacin cuts VAP burden in mechanically ventilated patients
16 Jan 2024
byAudrey Abella
In critically ill patients who have been on invasive mechanical ventilation (IMV) for at least 3 days, a subsequent 3-day course of preventive inhaled amikacin reduced the burden of ventilator-associated pneumonia (VAP) during 28 days of follow-up, findings from the AMIKINHAL trial have shown.
Inhaled amikacin cuts VAP burden in mechanically ventilated patients
16 Jan 2024mRNA boosters protect cancer patients against adverse COVID-19 outcomes
08 Jan 2024
byAudrey Abella
A prospective study from Singapore provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in individuals with cancer.